Eli Lilly has won FDA approval for its oral obesity drug Foundayo™ (orforglipron), but the stock bounce was short lived as investors pondered how much in sales it will generate this year as a price ...

Microgels mimic the mechanical properties of natural platelets to maximize the ability of the B peptides to create fibrin ...

Study findings indicate that environmentally relevant doses of OLA bioplastics may be “more toxic” to the placenta than ...

These pillars are composed of polyacrylamide hydrogel, a material whose stiffness can be adjusted to match the ~5 kPa ...

To model tumor biology, Emulate’s platform introduces stromal contents by tuning the extracellular matrix stiffness and composition, as well as recreating essential gradients. The method captures ...

Officials at Caring Cross emphasize that the organization is dedicated to ensuring the global affordability of advanced therapies.

Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.

Eli Lilly agrees to acquire sleep disorder drug developer Centessa Pharmaceuticals for approximately $7.8 billion, while ...

A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.

Overcoming efficacy, safety, and manufacturing hurdles through innovative personalized cancer vaccine design ...

From payload optimization to integrated GMP manufacturing, companies aim to elevate oncology ADCs to standard of care.

FDA approval of the first organoid-supported IND application augurs a future in which new approach methodologies supplant animal testing.